Liver Diseases  >>  Promacta (eltrombopag)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Promacta (eltrombopag) / Novartis
NCT00110799 / 2004-001469-16: SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C

Completed
2
75
US, Europe
SB497115, Placebo
GlaxoSmithKline
Hepatitis C, Chronic, Hepatitis C, Thrombocytopenia
10/06
11/06
NCT00861601: Phase 2, Pharmacokinetics Study of Eltrombopag in Japanese Thrombocytopenic Subjects With Chronic Liver Disease

Completed
2
38
Japan
eltrombopag 12.5 milligrams (mg) tablet, eltrombopag 25 mg tablet
GlaxoSmithKline
Liver Diseases
08/09
08/09
NCT01636778: Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients

Completed
2
45
Japan
SB-497115-GR
GlaxoSmithKline
Hepatitis C, Chronic
05/14
11/14

Download Options